Curanex Pharmaceuticals Inc (CURX) research

Curanex Pharmaceuticals Inc

Sector: Healthcare
Industry: Biotechnology
Last price: $4.58
As of: 2026-09-22

Curanex Pharmaceuticals Inc (CURX): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-04.

As of 2026-09-04, the latest of: this ticker's 13F holdings load, its latest SEC filing date, and its latest signal other than 13F-derived signals. Source: SEC EDGAR filings for CURX. Method and limitations.

LIVE TERMINAL

See CURX live in the terminal

Track CURX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live CURX terminal, free

Active signals for CURX

highINSTITUTIONAL_EXIT2026-07-24
TWO SIGMA INVESTMENTS, LP cut 67% of CURX (2026Q1)
All 2026-07-24 signals →

FREE, NO ACCOUNT

Every signal on CURX, as it fires

New filings, 13F moves and cross asset signals on CURX land in the record first.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in CURX (2026Q2)

Manager / security	Market value	% portfolio	QoQ
CITADEL ADVISORS LLCCUSIP 23126K106 · 2026Q2	$25K	0.00%	,
RENAISSANCE TECHNOLOGIES LLCCUSIP 23126K106 · 2026Q2	$14K	0.00%	,
TWO SIGMA INVESTMENTS, LPCUSIP 23126K106 · 2026Q2	$7K	0.00%	,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, CURX

8-K2026-09-04
SEC EDGAR ↗
8-K2026-08-17
SEC EDGAR ↗
10-Q2026-08-14
SEC EDGAR ↗
10-Q2026-05-14
SEC EDGAR ↗
8-K2026-05-14
SEC EDGAR ↗
8-K2026-05-07
SEC EDGAR ↗
8-K2026-04-02
SEC EDGAR ↗
10-K2026-03-30
SEC EDGAR ↗
8-K2026-03-06
SEC EDGAR ↗
8-K2026-01-05
SEC EDGAR ↗

CURX against its peers

CURX's return on equity of -37.7% ranks in the 92nd percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.

Metric	CURX	Peer median	Percentile	n
Revenue FY	n/a	1.5M	n/a	14
Gross margin	n/a	64.1%	n/a	8
Operating margin	n/a	-631.0%	n/a	13
Net margin	n/a	-484.6%	n/a	13
Return on equity	-37.7%	-188.9%	92	17

Peers (21): OSRH, ADTX, EVGN, CLGN, BOLT, AAGH, RVPH, AIM, IMNN, CNSP, LEXX, ACXP, KAPA, CDIO, TRAW, ALZN, PCSA, ENSC, BGMS, CELZ, ZEOX. Left out: ADAPY (no annual filing), ENVB (no annual filing), XTLB (period gap), CUBT (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (CURX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more CURX signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CURXand get the insider, 13F, options, and confluence read in one view.